Orthodontics is rapidly emerging as the preferred specialty for DSO platform building, driven by economics that are uniquely suited to the roll-up model. Unlike general dentistry, where revenue is fragmented across dozens of procedure codes with variable insurance reimbursement, orthodontics concentrates around a predictable product — comprehensive treatment plans averaging $5,000–$7,000 per case — with high consumer demand and significant out-of-pocket payment. The clear aligner revolution, led by Invisalign and a growing cohort of competitors, has further standardized the delivery model, making it easier to systematize across multiple locations. PE-backed ortho platforms are capitalizing on this, building networks that combine branded consumer marketing with centralized clinical protocols and supply chain leverage.

The structural appeal is straightforward: orthodontic practices generate higher margins than general dentistry, with EBITDA margins routinely exceeding 30% in well-managed single-specialty groups versus 15–20% for general practices. Patient lifetime value is concentrated — a typical ortho case involves 12–24 months of treatment with scheduled visits, creating predictable revenue streams that PE investors prize. The consumer demand side is equally compelling: orthodontic treatment starts among adults have grown steadily, with the American Association of Orthodontists reporting that adults now represent roughly 30% of all new cases, up from 20% a decade ago. Direct-to-consumer competitors like SmileDirectClub's collapse in 2023 removed a low-cost alternative, pushing patients back toward provider-supervised care.

For the broader DSO ecosystem, the orthodontic roll-up wave has several implications. First, it validates the specialty-platform thesis — the idea that focused clinical models outperform diversified networks in terms of operational efficiency and valuation multiples. Ortho platforms regularly trade at 10–14x EBITDA, a significant premium to general dental DSOs. Second, it creates competitive tension with general DSOs that have in-house orthodontic departments; as standalone ortho platforms scale, they may begin pulling referral volume away from multi-specialty groups. Third, the model is replicable — oral surgery, periodontics, and pediatric dentistry all share characteristics that lend themselves to platform consolidation, and ortho's success will likely accelerate investment in these adjacent specialties.

Watch for which PE firms place the next major bet on ortho platforms — KKR, Harvest Partners, and Gryphon Investors have already established positions in the space, and new entrants are circling. Monitor whether the major general DSOs respond by spinning out or separately capitalizing their orthodontic divisions. Track clear aligner pricing dynamics, as increased competition from brands like uLab, SureSmile, and Spark could compress case fees and force platforms to compete on volume rather than margin. And pay attention to the adult ortho growth rate — if consumer demand plateaus, the economics that make ortho platforms attractive to PE could shift quickly.